Retrieve available abstracts of 118 articles: HTML format
Single Articles
June 2025
CAVALLARO G, Salmoiraghi S, Cavagna R, Pavoni C, et al Clinical impact of tyrosine kinases related mutations in NPM1 mutated acute
myeloid leukaemia: A report from the Northern Italy Leukaemia Group (NILG)
multicentre randomized trial 02/06.
Leuk Res. 2025;153:107702. PubMedAbstract available
May 2025
HASLINGER S, Schinnerl D, Konig M, Inthal A, et al Identification of a novel amplified PAX5::RBPMS fusion gene in pediatric B-cell
acute lymphoblastic leukemia.
Leuk Res. 2025;154:107722. PubMed
HAMMAMI MB, Qasim A, Shah A, Zhang H, et al Cutaneous manifestations of large granular lymphocytic leukemia: A case report
and systematic review.
Leuk Res. 2025;154:107720. PubMed
JOHNSON-ANSAH H, Charbonnier A, Etienne G, Roy L, et al Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions:
Real-life study from the French CML group Fi-LMC.
Leuk Res. 2025;154:107716. PubMedAbstract available
SHICHIJO T, Yasunaga JI Stratagems of HTLV-1 for persistent infection and the resultant oncogenesis:
Immune evasion and clonal expansion.
Leuk Res. 2025;152:107680. PubMedAbstract available
April 2025
KONDO K, Najima Y, Sadato D, Hirama C, et al Pre-transplant blinatumomab and/or inotuzumab ozogamicin therapy for
relapsed/refractory acute lymphoblastic and B/myeloid mixed phenotype acute
leukemia in adults.
Leuk Res. 2025;153:107704. PubMedAbstract available
AUBREY BJ, Blonquist T, McMasters M, Hobbs G, et al A phase I clinical trial of lenalidomide combined with bortezomib for acute
myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell
transplantation.
Leuk Res. 2025;153:107693. PubMedAbstract available
ZHANG W, Cui Y, Wu J, Chen Y, et al Incidence and risk factors of venous thromboembolism in patients with acute
Leukemia: A systematic review and meta-analysis.
Leuk Res. 2025;153:107694. PubMedAbstract available
VARGAS LCZ, Ortiz-Ortiz J, Martinez YA, Viguri GEC, et al Identification of ZNF384 as a regulator of epigenome in leukemia.
Leuk Res. 2025;153:107691. PubMedAbstract available
HIBINO Y, Fujisawa S, Fujimaki K, Hagihara M, et al Clinical applicability of the ELN2020 criteria for tyrosine kinase inhibitor
discontinuation in chronic myeloid leukemia: insights from a multicenter
retrospective study in real-world practice.
Leuk Res. 2025;152:107689. PubMedAbstract available
AL MALKI MM, Minden MD, Rich ES, Hill JE, et al Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory
acute myeloid leukemia: A phase 1 study.
Leuk Res. 2025;152:107690. PubMedAbstract available
March 2025
DHANGAR S, Shanmukhaiah C, Ghatanatti J, Sawant L, et al Comprehensive analysis of tyrosine kinase domain mutations and imatinib
resistance in chronic myeloid leukemia patients.
Leuk Res. 2025;152:107679. PubMedAbstract available
February 2025
KOGURE Y, Kataoka K Clinical and therapeutic significance of genetic profiling in adult T-cell
leukemia/lymphoma.
Leuk Res. 2025;151:107676. PubMedAbstract available
THUY VT, Viet NL, Nghia NT, Cangelosi G, et al The impact of the solute carrier gene superfamily polymorphisms on tyrosine
kinase inhibitors responses among chronic myeloid leukemia: A meta-analysis.
Leuk Res. 2025;151:107673. PubMedAbstract available
WU Q, Zhong L, Zhang G, Han L, et al Complementing therapeutic strategies for acute myeloid leukemia: Signaling
pathways and targets of traditional Chinese medicine.
Leuk Res. 2025;151:107672. PubMedAbstract available
SHI S, Zhou Q, Zhao D, Zarif M, et al Molecular genetic characterization of mixed-phenotype acute leukemia (MPAL) with
BCR::ABL1 fusion.
Leuk Res. 2025;151:107665. PubMedAbstract available
MAHMOOD NH, Kadir DH Sparsity regularization enhances gene selection and leukemia subtype
classification via logistic regression.
Leuk Res. 2025;150:107663. PubMedAbstract available
KOMROKJI Z, Ali NA, Xie Z, Chan O, et al Serum hypoalbuminemia is an independent prognostic factor in Chronic
Myelomonocytic Leukemia (CMML).
Leuk Res. 2025;150:107662. PubMedAbstract available
January 2025
YOSHIDA N, Hida A, Sakata R Trends of changes in human T-cell leukemia virus type 1 epidemiology in Japan and
globally.
Leuk Res. 2025;150:107654. PubMedAbstract available
YOSHIMITSU M Targeted antibody therapy as a treatment strategy for aggressive adult T-cell
leukemia/lymphoma.
Leuk Res. 2025;149:107653. PubMedAbstract available
DENG A, Zhang F, Wang M, Jiang D, et al A novel KMT2A::DCP1A fusion gene in acute myeloid leukemia.
Leuk Res. 2025;149:107645. PubMed
EPSTEIN-PETERSON ZD, Gurumurthi A, Horwitz SM New treatments for adult T-cell leukemia/lymphoma.
Leuk Res. 2025;149:107642. PubMedAbstract available
FONTECHA MB, Del Rosario Anadon M, Lahitou IMM, Weich N, et al Exploring the significance of MDM2 gene promoter variants in chronic myeloid
leukemia.
Leuk Res. 2025;149:107644. PubMedAbstract available
WETERINGS DA, Rowan AG, Cook LB Immunological aspects of HTLV-1 persistence; for the prevention and treatment of
Adult T-cell leukaemia-lymphoma (ATL).
Leuk Res. 2025;148:107635. PubMedAbstract available
WU H, Luo H, Wang M, Du Y, et al NAP1L5 promotes epithelial-mesenchymal transition by regulating PEG10 expression
in acute myeloid leukaemia.
Leuk Res. 2025;148:107623. PubMedAbstract available
December 2024
ZHAO R, Cui Y, Li D, Guo X, et al Anlotinib enhances the pro-apoptotic effect of APG-115 on acute myeloid leukemia
cell lines by inhibiting the P13K/AKT signaling pathway.
Leuk Res. 2024;149:107637. PubMedAbstract available
SHAHZAD M, Iqbal Q, Amin MK, Irfan S, et al Outcomes of hematopoietic stem cell transplantation in primary plasma cell
leukemia: A systematic review and meta-analysis.
Leuk Res. 2024;148:107640. PubMedAbstract available
LI M, Zhang S, Wei J, Liu M, et al The increase in the expression of circRNAs may contributes to a poor prognosis in
acute myeloid leukemia: A systematic review and meta-analysis.
Leuk Res. 2024;148:107639. PubMedAbstract available
LI J, Fu S, Ye C, Li J, et al Combination therapy involving azacitidine for acute myeloid leukemia patients
ineligible for intensive chemotherapy.
Leuk Res. 2024;148:107638. PubMedAbstract available
KARUBE K, Sakihama S, Takatori M, Morichika K, et al Recent progress in pathological understanding of adult T-cell leukemia/lymphoma
in the new classification era.
Leuk Res. 2024;148:107634. PubMedAbstract available
FUJI S Chemotherapy and allo-HSCT for young patients with aggressive ATL.
Leuk Res. 2024;147:107596. PubMedAbstract available
November 2024
ROUZBAHANI M, Mousavi SA, Hajianfar G, Ghanaati A, et al Predictive modeling of outcomes in acute leukemia patients undergoing allogeneic
hematopoietic stem cell transplantation using machine learning techniques.
Leuk Res. 2024;148:107619. PubMedAbstract available
KIM JY, Vijayakumar KA, Cho GW Exploring the impact of methylation aging on acute myeloid leukemia: Insights
from the aging clock.
Leuk Res. 2024;148:107620. PubMedAbstract available
QIAN S, Gong J, Shen X, Chen M, et al Causal role of genetically predicted 731 immune cell phenotypes in chronic
lymphatic leukemia: A bidirectional Mendelian randomization study.
Leuk Res. 2024;148:107621. PubMedAbstract available
WANG X, Chen T Diagnostic challenges and criteria application in a 70-year-old patient with
oligo monocytic chronic granulomonocytic leukemia: A case report.
Leuk Res. 2024;147:107616. PubMed
MISHRA R, Calabrese C, Jain AG, Singh A, et al Association between myeloid disorders and adult onset-inflammatory syndromes,
successful treatment with JAK-inhibitors: Case series and literature review.
Leuk Res. 2024;146:107584. PubMedAbstract available
October 2024
ISFORT S, Gambacorti-Passerini C, Brummendorf TH, Smith BD, et al The effect of body mass index on the safety of bosutinib in patients with chronic
leukemia: A post hoc pooled data analysis.
Leuk Res. 2024;147:107609. PubMed
CHIEN KS, Rodriguez-Sevilla JJ, Alvarado Y, Montalban-Bravo G, et al A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG
176) in patients with myelodysplastic syndromes after hypomethylating agent
failure.
Leuk Res. 2024;147:107602. PubMed
EL HAJJ H, Hermine O, Bazarbachi A Therapeutic advances for the management of adult T cell leukemia: Where do we
stand?
Leuk Res. 2024;147:107598. PubMedAbstract available
LI T, Cui Q, Liu S, Li Z, et al Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance
treatment significantly improves survival outcomes in relapsed/refractory B-ALL
patients.
Leuk Res. 2024;145:107569. PubMedAbstract available
September 2024
PRIYA, Garg M, Talwar R, Bharadwaj M, et al Clinical relevance of long non-coding RNA in acute myeloid leukemia: A systematic
review with meta-analysis.
Leuk Res. 2024;147:107595. PubMedAbstract available
CHEN R, AlHumaid M, Daher-Reyes G, Atenafu EG, et al Outcome of adolescents and young adult acute myeloid leukemia patients compared
with middle-aged patients: A single centre retrospective experience.
Leuk Res. 2024;147:107586. PubMedAbstract available
XIAO Y, Xiao L, Xu X, Guan X, et al Development and validation of a predictive model for tumor lysis syndrome in
childhood acute lymphoblastic leukemia.
Leuk Res. 2024;146:107587. PubMedAbstract available
FAIZ AS, Guo S, Sridharan A, Lin Y, et al Risk factors and mortality associated with venous thromboembolism in the elderly
US population with chronic lymphocytic leukemia.
Leuk Res. 2024;146:107585. PubMedAbstract available
ACHAR RK, McCormick BJ, Dworkin E, Geramita EM, et al Outcomes of patients with acute myeloid leukemia treated with intensive therapy
after failure of venetoclax-inclusive, less-intensive therapy.
Leuk Res. 2024;146:107577. PubMed
WU S, Liu F, Gai Y, Carter J, et al Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax
results in promising antileukemic activity against FLT3-ITD AML.
Leuk Res. 2024;144:107547. PubMedAbstract available
August 2024
DESAI A, Samara Y, Yang D, Ball B, et al Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and
chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell
transplantation.
Leuk Res. 2024;145:107565. PubMedAbstract available
DIAZ MARTINEZ JP, de Maraumont TA, Camacho LM, Garcia L, et al Cost-effectiveness of blinatumomab for the treatment of B?precursor acute
lymphoblastic leukemia pediatric patients with high?risk first?relapse in Mexico.
Leuk Res. 2024;145:107560. PubMedAbstract available
CINGELOVA S, Mikuskova E, Demitrovicova L, Mikudova V, et al Distinctive features associated with differentiation syndrome in acute
promyelocytic leukemia in patients treated by all-trans retinoic acid and arsenic
trioxide.
Leuk Res. 2024;145:107567. PubMedAbstract available
FU Q, Wang Y, Liu H, Gao H, et al Triplet therapy with gilteritinib, venetoclax, and azacitidine for
relapsed/refractory FLT3(mut) acute myeloid leukemia.
Leuk Res. 2024;145:107564. PubMedAbstract available
TRAVAGLINI S, Silvestrini G, Attardi E, Fanciulli M, et al Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia.
Leuk Res. 2024;145:107568. PubMedAbstract available
SHIMIZU H, Kato J, Tanoue S, Kimura SI, et al Allogeneic stem cell transplant with TBI-based myeloablative conditioning in
adolescents and young adults with Philadelphia chromosome-negative ALL treated
with pediatric protocols.
Leuk Res. 2024;144:107562. PubMedAbstract available
BOISCLAIR S, Zhou E, Naing P, Thakur R, et al Less is more: An analysis of venetoclax and hypomethylating agent post-induction
treatment modifications in AML.
Leuk Res. 2024;143:107545. PubMedAbstract available
GALIENI P, Troiani E, Picardi P, Angelini M, et al Unmutated IGHV at diagnosis in patients with early stage CLL independently
predicts for shorter follow-up time to first treatment (TTFT).
Leuk Res. 2024;143:107541. PubMedAbstract available
EDWARDS K, Manoussaka M, Sayed U, Tsertsvadze T, et al MD-1 downregulation is associated with reduced cell surface CD180 expression in
CLL.
Leuk Res. 2024;143:107540. PubMedAbstract available
VIANNA DT, Reis Monte-Mor BDC, Noronha EP, Gutiyama LM, et al Molecular characterization of V(D)J rearrangements in immature acute leukemias.
Leuk Res. 2024;143:107521. PubMedAbstract available
July 2024
CUI H, Ma Y, Han S, Zhang X, et al Arsenic trioxide regulates the glycolytic pathway to treat acute promyelocytic
leukemia by inhibiting RPL22L1.
Leuk Res. 2024;144:107550. PubMedAbstract available
MOLICA M, Perrone S, Rossi M, Giannarelli D, et al The impact of different FLT3-inhibitors on overall survival of de novo acute
myeloid leukemia: A network meta-analysis.
Leuk Res. 2024;144:107549. PubMedAbstract available
KONG C, Wu M, Lu Q, Ke B, et al PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic
lymphocytic leukemia.
Leuk Res. 2024;144:107548. PubMedAbstract available
MESTRUM SGC, Roanalis BYV, de Wit NCJ, Drent RJM, et al MDS and AML show elevated fractions of CD34-positive blast cell populations with
a high anti-apoptotic versus proliferation ratio.
Leuk Res. 2024;142:107520. PubMedAbstract available
June 2024
PARMAR K, Kundu R, Maiti A, Ball S, et al Updates in biology, classification, and management of acute myeloid leukemia with
antecedent hematologic disorder and therapy related acute myeloid leukemia.
Leuk Res. 2024;144:107546. PubMedAbstract available
XU Z, Zhang T, Hao J, Liu D, et al Identification of clonal relationship and prognostic significance in acute
myeloid leukemia patients with concomitant increase in mast cells.
Leuk Res. 2024;143:107539. PubMed
SHIN DY, Park S, Jang E, Kong JH, et al Early dose reduction of dasatinib does not compromise clinical outcomes in
patients with chronic myeloid leukemia: A comparative analysis of two prospective
trials.
Leuk Res. 2024;143:107542. PubMedAbstract available
JESTRABEK H, Kohlhas V, Hallek M, Nguyen PH, et al Impact of leukemia-associated macrophages on the progression and therapy response
of chronic lymphocytic leukemia.
Leuk Res. 2024;143:107531. PubMedAbstract available
PANDA T, Rainchwar S, Singh R, Singh A, et al Real world outcome of B ALL with t (1; 19) (q23; p13)/TCF3::PBX1 in adolescents
and adults treated with intensive regimes.
Leuk Res. 2024;141:107506. PubMedAbstract available
May 2024
ODUTOLA PO, Olorunyomi PO, Olorunyomi I Single vs double umbilical cord blood transplantation in acute leukemia:
Systematic review and meta-analysis.
Leuk Res. 2024;142:107517. PubMedAbstract available
RISUENO A, See WL, Bluemmert I, de Botton S, et al Somatic gene mutation patterns and burden influence outcomes with enasidenib in
relapsed/refractory IDH2-mutated AML.
Leuk Res. 2024;140:107497. PubMedAbstract available
April 2024
SUN M, Li S, Liu Z, Ma S, et al Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic
myeloid leukemia in the chronic phase: A real-world single-center retrospective
study, with a focus on premature drug discontinuation.
Leuk Res. 2024;142:107507. PubMedAbstract available
INDRAN T, Das T, Muirhead J, O'Brien M, et al Donor Lymphocyte Infusion (DLI) post allogeneic stem cell transplant (allo-SCT)
in Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS). A
longitudinal retrospective study using peripheral blood (PB) CD34(+) and CD3(+)
donor chim
Leuk Res. 2024;142:107504. PubMedAbstract available
MOHEBBI A, Shahriyary F, Farrokhi V, Bandar B, et al A systematic review of second-generation FLT3 inhibitors for treatment of
patients with relapsed/refractory acute myeloid leukemia.
Leuk Res. 2024;141:107505. PubMedAbstract available
ZAD Z, Bonecker S, Wang T, Zalcberg I, et al Prediction of deep molecular response in chronic myeloid leukemia using
supervised machine learning models.
Leuk Res. 2024;141:107502. PubMed
BERTON G, Sedaki B, Collomb E, Benachour S, et al Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly
diagnosed acute myeloid leukemia.
Leuk Res. 2024;141:107500. PubMedAbstract available
DONG S, Premnath N, Sadeghi N, Kainthla R, et al Racial and ethnic disparities in Acute Myeloid Leukemia: 15-year experience at a
safety net hospital system.
Leuk Res. 2024;141:107503. PubMedAbstract available
ASHOURI K, Ginosyan AA, Chu M, Hom B, et al Donor matters: Donor selection impact on hematopoietic stem cell transplantation
outcomes in Hispanic patients with B-cell acute lymphocytic leukemia: Insights
from a myeloablative HSCT study.
Leuk Res. 2024;141:107501. PubMedAbstract available
HU X, Cao P, Wang F, Wang T, et al Alternative polyadenylation quantitative trait loci contribute to acute myeloid
leukemia risk genes regulation.
Leuk Res. 2024;141:107499. PubMedAbstract available
SMITH BD, Brummendorf TH, Roboz GJ, Gambacorti-Passerini C, et al Efficacy and safety of bosutinib in patients treated with prior imatinib and/or
dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.
Leuk Res. 2024;139:107481. PubMedAbstract available
MORSY MM, Azzam AY, Elamin O, Elswedy A, et al Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid
leukemia: A subgroup based meta-analysis.
Leuk Res. 2024;140:107498. PubMedAbstract available
March 2024
YIGIT KAYA S, Mutlu YG, Malkan UY, Mehtap O, et al Single agent vemurafenib or rituximab-vemurafenib combination for the treatment
of relapsed/refractory hairy cell leukemia, a multicenter experience.
Leuk Res. 2024;140:107495. PubMedAbstract available
MUTHIAH C, Narra R, Atallah E, Juan W, et al Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era
of novel therapies using the SEER registry.
Leuk Res. 2024;140:107496. PubMedAbstract available
BRUNETTI M, Iasenza IA, Jenner AL, Raynal NJ, et al Mathematical modelling of clonal reduction therapeutic strategies in acute
myeloid leukemia.
Leuk Res. 2024;140:107485. PubMedAbstract available
IKOMA-COLTURATO MRV, Severino AR, Dos Santos Tosi JF, Bertolucci CM, et al Clinical validation of a 10-color flow cytometry panel to detect measurable
residual disease in acute myeloid leukemia.
Leuk Res. 2024;140:107482. PubMed
GARCIA-MANERO G, Kazmierczak M, Wierzbowska A, Fong CY, et al Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid
leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase
III study.
Leuk Res. 2024 Mar 12:107480. doi: 10.1016/j.leukres.2024.107480. PubMedAbstract available
WAN CL, Huang YH, Huang SM, Xu YL, et al Investigations of the prognostic value of RUNX1 mutation in acute myeloid
leukemia patients: Data from a real-world study.
Leuk Res. 2024;139:107483. PubMedAbstract available
PAN L, Li Y, Gao H, Lai X, et al Clinical features and management of germline CEBPA-mutated carriers.
Leuk Res. 2024;138:107453. PubMedAbstract available
SIDI Y, Dong C, Wu Y, Faller DV, et al A critical evaluation of the EFS endpoint in AML: Does induction treatment
failure timing have a profound impact on study design and results?
Leuk Res. 2024;138:107465. PubMedAbstract available
February 2024
BOURNE G, Diebold K, Espinoza-Gutarra M, Al-Kadhimi Z, et al Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy
in core-binding factor acute myeloid leukemia.
Leuk Res. 2024;139:107467. PubMedAbstract available
ZHONG S, Kurish H, Walchack R, Li H, et al Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of
relapsed or refractory acute myeloid leukemia.
Leuk Res. 2024;139:107468. PubMedAbstract available
OSMAN AEG, Rets A, Patel AB KRAS mutations, autoimmunity and female sex in chronic myelomonocytic leukemia.
Leuk Res. 2024;138:107466. PubMed
SANCHEZ-PETITTO G, Goloubeva OG, Masur J, Childress J, et al Clinical outcomes of patients with acute myeloid leukemia and cardiovascular
disease.
Leuk Res. 2024;138:107456. PubMedAbstract available
SUDO H, Tonoyama Y, Ikebe E, Hasegawa H, et al Proteomic analysis of adult T-cell leukemia/lymphoma: A biomarker identification
strategy based on preparation and in-solution digestion methods of total
proteins.
Leuk Res. 2024;138:107454. PubMedAbstract available
GOULART H, Sastow D, Moshier E, Martin L, et al Systematic review and meta-analysis evaluating clinical outcomes in adult acute
myeloid leukemia patients with central nervous system involvement.
Leuk Res. 2024;137:107452. PubMedAbstract available
ELGHETANY MT, Patnaik MM, Khoury JD Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes /
germline predisposition syndromes: Back under the microscope.
Leuk Res. 2024;137:107441. PubMedAbstract available
RAMOS-CILLAN S, Lainez-Gonzalez D, Solan L, Blas C, et al When the devil is in the details: Similarities and differences between WHO and
ICC classifications of AML.
Leuk Res. 2024;137:107440. PubMed
January 2024
BOUCHER L, Rozalska L, Sorel N, Olivier G, et al Emergence of secondary fusions in chronic myeloid leukemia as a driver of
tyrosine kinase inhibitor resistance and blast crisis transformation.
Leuk Res. 2024;137:107439. PubMed
OH I, Hatano K, Ikeda T, Toda Y, et al Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus
dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia
in adults.
Leuk Res. 2024;137:107438. PubMed
DIDI I, Alliot JM, Dumas PY, Vergez F, et al Artificial intelligence-based prediction models for acute myeloid leukemia using
real-life data: A DATAML registry study.
Leuk Res. 2024;136:107437. PubMedAbstract available
KLINK AJ, Gajra A, Knoth RL, Marshall L, et al Corrigendum to "Real-world clinical outcomes with enasidenib in relapsed or
refractory acute myeloid leukemia" [Leuk. Res. (2022) 106946].
Leuk Res. 2024 Jan 9:107430. doi: 10.1016/j.leukres.2023.107430. PubMed
KUSNE Y, Lasho T, Finke C, Patnaik MM, et al VEXAS syndrome in a patient with DDX41 germline predisposition syndrome.
Leuk Res. 2024;136:107432. PubMed
KHANNA V, Lu R, Kumar J, Molina A, et al The clinical, molecular, and prognostic features of the 2022 WHO and ICC
classification systems for myelodysplastic neoplasms.
Leuk Res. 2024;136:107433. PubMedAbstract available
December 2023
NOTARANTONIO AB, Roth-Guepin G, Bonmati C, Divoux M, et al A new sequential conditioning regimen based on CPX- 351/Vyxeos ("Vyx-Seq") in
patients with higher risk myelodysplastic syndromes.
Leuk Res. 2023;135:107405. PubMed
November 2023
ASHBY M, Fleming S, Teh TC, Tiong IS, et al Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell
transplant in patients with acute myeloid leukemia failing conventional intensive
chemotherapy.
Leuk Res. 2023;136:107429. PubMed
URBINO I, Secreto C, Apolito V, Olivi M, et al Sorafenib in combination with intensive chemotherapy for relapsed or refractory
FLT3-ITD positive acute myeloid leukemia: A two centers experience.
Leuk Res. 2023 Nov 18:107421. doi: 10.1016/j.leukres.2023.107421. PubMed
ZHAO D, Zhou Q, Zarif M, Eladl E, et al AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients
with 20% or more blasts.
Leuk Res. 2023;134:107376. PubMedAbstract available
October 2023
RAVINDRA A, Acharya L, Loeffler B, Mott S, et al Venetoclax-based therapy in treatment-naive and relapsed/refractory acute myeloid
leukemia.
Leuk Res. 2023;135:107407. PubMedAbstract available
ANSARI F, Behfar M, Jafari L, Mohseni R, et al A comprehensive comparison between TBI vs non-TBI-based conditioning regimen in
pediatric patients with acute lymphoblastic leukemia: A systematic review and
meta-analysis.
Leuk Res. 2023;135:107416. PubMedAbstract available
ZHANG F, Du H, Hu C, Song Y, et al A new prognostic risk model for acute myeloid leukemia patients based on
telomere-related genes.
Leuk Res. 2023;135:107404. PubMedAbstract available
SHERBAN A, Fredman D, Shimony S, Yeshurun M, et al Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the
treatment for newly diagnosed and relapsed/refractory patients with AML - A
systematic review.
Leuk Res. 2023;133:107368. PubMedAbstract available
September 2023
JIMENEZ-VICENTE C, Martinez-Roca A, Pomares H, Castano-Diez S, et al Venetoclax with hypomethylating agents might lead to eradication of measurable
residual disease (MRD) persisting after intensive chemotherapy in acute myeloid
leukemia (AML) patients with mutated NPM1 and rearranged CBF.
Leuk Res. 2023;135:107403. PubMed
JAMY OH, Kasner M, Wall S, Ingram S, et al Integrating electronic geriatric assessment and frailty screening for adults with
acute myeloid leukemia to drive personalized treatment decisions.
Leuk Res. 2023;134:107393. PubMedAbstract available
GURNEY M, Greipp PT, Gliem T, Knudson R, et al TET2 somatic copy number alterations and allelic imbalances in chronic
myelomonocytic leukemia.
Leuk Res. 2023;134:107391. PubMed
SINGH C, Karunakaran P, Yanamandra U, Jindal N, et al Factors associated with thrombo-hemorrhagic deaths in patients with Acute
Promyelocytic leukemia treated with Arsenic Trioxide and all-trans retinoic acid.
Leuk Res. 2023;134:107392. PubMedAbstract available
PATEL SA, Bello E, Wilks A, Gerber JM, et al Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023
update of trials and tribulations.
Leuk Res. 2023;134:107388. PubMedAbstract available
HIRT CK, Padmanabha N, Michaels PD Cohesin complex mutations in myeloid neoplasms are enriched for SRSF2, RUNX1,
TET2, and NRAS co-mutations and morphologic dysplasia.
Leuk Res. 2023;132:107357. PubMed
BRANDWEIN JM, Ebeling K, Ding L, Liew E, et al Changing frontline AML treatment patterns from 2013 to 2022.
Leuk Res. 2023;132:107354. PubMedAbstract available
XIE W, Wang Z, Guo X, Guan H, et al MiR-409-3p regulates the proliferation and apoptosis of THP-1 through targeting
Rab10.
Leuk Res. 2023;132:107350. PubMedAbstract available
August 2023
KHADADAH FM, Cerquozzi S, Olney HJ, Fraga C, et al Canadian real-world experience of asciminib treatment in heavily pre-treated
chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine
kinase inhibitor (TKI) therapy.
Leuk Res. 2023;133:107374. PubMedAbstract available
BOULIGNY IM, Murray G, Ho T, Doyel M, et al Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
Leuk Res. 2023;134:107370. PubMed
ZHAO ZY, Tang N, Lin LE A rare BCR-ABL1 transcript in chronic myeloid leukemia: Case report and
literature review.
Leuk Res. 2023;133:107369. PubMedAbstract available